Crystalys Therapeutics Announces $130 Million Series B Financing to Advance Global Phase 3 Development and Commercialization of Dotinurad for Gout July 22, 2026
Crystalys Therapeutics Doses First Patients in New Phase 2 Trial of Dotinurad for Difficult-to-Treat Gout May 27, 2026
Crystalys Therapeutics Appoints Tim Walbert, Former Horizon Therapeutics CEO, as Independent Board Director February 11, 2026
Crystalys Therapeutics Expands Phase 3 RUBY Study With First Patients Dosed at European Sites February 2, 2026
Crystalys Therapeutics Expands Leadership Team with Appointment of Justin Thacker as Chief Financial Officer to Support Advancement of Phase 3 Trials of Dotinurad January 21, 2026
